Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Rebecca MathewPietro Di SantoRichard G JungJeffrey A MarbachJordan HutsonTrevor SimardF Daniel RamirezDavid T HarnettAnas MerdadAws AlmuflehWilly WengOmar Abdel-RazekShannon M FernandoKwadwo KyeremantengJordan BernickGeorge A WellsVincent ChanMichael FroeschlMarino LabinazMichel R Le MayJuan J RussoBenjamin HibbertPublished in: The New England journal of medicine (2021)
In patients with cardiogenic shock, no significant difference between milrinone and dobutamine was found with respect to the primary composite outcome or important secondary outcomes. (Funded by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; ClinicalTrials.gov number, NCT03207165.).